What 443 adults said about trust, read from St. Louis

We asked 443 Midwest adults what would genuinely persuade them toward ketamine-based depression care, and one answer buried the rest: their own doctor, at 74 percent.

If you read this in St. Louis, that finding is worth more than any clinic homepage, because it shows where the decision really gets made. First, one piece of housekeeping most survey coverage skips.

What this study can tell you about St. Louis, and what it cannot

Our respondents, 443 adults between 18 and 64, came from ten Midwest states including Missouri. This article leaves aside the survey's small state and metro breakdowns; every percentage below describes the ten-state sample as a whole. Treat the numbers as a regional temperature, not a local measurement, and the practical notes further down as ordinary local context, not something the survey proved about your zip code. Every number here has passed final panel validation.

The trust question

We asked respondents whose advice would carry them over the line on this kind of treatment, and the answers were unusually lopsided. A doctor they already see took 74 percent. Someone in the family or a close friend took 18. Someone from the service or first responder world whose posts they read took 4, an advertisement 2, and a podcast host 1.

Beyond the two personal answers, nothing cleared single digits. Whatever you have seen advertised, the public in this region is waiting on a person with a stethoscope and access to their chart.

The demand underneath it

For most people who answered, this is not a curiosity question. In all, 72 percent described depression, anxiety, or PTSD lingering despite ordinary prescriptions, either their own (37 percent), a loved one's (22 percent), or both (13 percent), with 28 percent reporting none.

Nearly three in four is a striking share for a panel not screened for patients. Treatment-resistant depression is usually discussed as a narrow clinical category; in this sample it looked like a household experience.

Coverage sits in front of everything else

Asked to name the two factors that matter most when picking a provider for this care, 85 percent chose insurance coverage and 43 percent chose being close to home. Convenience matters to many people; money matters to nearly everyone.

Coverage is not a detail to work out later. For most people we surveyed, it decides whether there is a later at all.

The payer picture behind that answer deserves attention. With more than one choice allowed, commercial coverage was the most-checked box at 39 percent and Medicaid the runner-up at 37; Medicare covered 23 percent and TRICARE a small 5, while 9 percent went without insurance, with 2 percent declining to say. Commercial insurance is the largest block, but only barely; Medicaid is nearly its equal. Any assumption that this treatment is a private-pay product for the commercially insured runs against the makeup of the region.

Where people want to actually receive it

We also asked how respondents would like to receive treatment if several formats were offered. A clinic in person led with 44 percent. A clinic-then-home sequence came in at 23 percent and home telehealth at 22, and 11 percent had no preference.

The plurality wants a room, a clinician, and supervision, which happens to match how the FDA-approved version works. Esketamine, marketed as Spravato, won approval for treatment-resistant depression under a rule that each dose be supervised in a certified setting, with the patient watched afterward. It does not arrive in the mail. Brain Recovery Centers, which offers it, explains how its Spravato visits are run.

Ketamine that telehealth companies send home is a separate and considerably grayer category, with different oversight and a different evidence picture. The two get mentioned in one breath online, and they should not be. The first question for any provider is which of the two it actually offers.

Practical notes for a St. Louis reader

None of what follows came from the survey. It is everyday context that makes the findings usable where you live.

• Your primary care office is the front door, and most people want it that way. You need not ask for a specific drug; a written list of what has been tried, for how long, and how it went is enough to start.
• Ask about coverage before driving anywhere. Call your plan, ask what is covered for treatment-resistant depression, whether prior authorization applies, and what documentation it wants, then ask the clinic the same and see whether the answers match.
• If you are on Medicaid, Missouri's program is MO HealthNet, and your coverage depends on your plan. Rules change, so confirm details with the plan itself.
• Ask any clinic whether it is certified to give esketamine under supervision or is a telehealth service shipping ketamine home, and get the answer in words you can repeat to your doctor.
• Distance matters, but the survey puts it second. A clinic where you can afford to finish a course beats a closer one where you cannot.

The necessary caution

This is market research about how people decide on care, not clinical evidence, medical advice, or a promise that any treatment helps. Whether ketamine or esketamine suits you turns on your history, your medications, and your medical picture, which only a clinician who sees all three can weigh.

If any of this lands because things have gotten dark lately, reach out tonight rather than carrying it alone. Dialing or texting 988 connects you with a trained person, weekends and holidays included.

Methodology

This publisher paid for and commissioned survey ID 395586438, which stayed in the field on Pollfish's consumer panel until late June, closing on June 23, 2026. Its 443 respondents ranged in age from 18 to 64 and were drawn from ten Midwest states. Results were not broken out by city or state, so no figure here represents St. Louis, Missouri, or any single place. Where a question allowed several answers, shares total above 100. Everything reported passed the panel's final validation.